

CDC PrEP Clinical Practice Guideline and Strategies for Ending the HIV Epidemic in the US (On-Demand)



Presenters: Demetre C. Daskalakis, MD, MPH, and Dawn K. Smith, MD, MS, MPH
Moderator: Raphael J. Landovitz, MD

Release date: March 22, 2022

Expiration date: March 22, 2023

CME Credit Available: 1.25 AMA PRA Category 1 Credits™

Assessment of Needs

This webinar will provide a concise summary of the latest 2021 update to the Centers for Disease Control and Prevention's pre-exposure prophylaxis (PrEP) guidelines. The guidelines include new clinical guidance for the prescription of cabotegravir injections as PrEP for sexually active adults, which was approved by the US Food and Drug Administration in December 2021. Additionally, it provides key changes in testing and monitoring patients who are starting or taking PrEP.

This webinar is part 1 of a 2-part webinar series on the updated PrEP guidelines. Part 2 will discuss the implementation of long-acting PrEP in a clinic, in a case-based panel discussion. Date and time to be announced.

Learning Objectives

At the end of this webinar, participants will be able to:

- Assess HIV trends, prevalence, and infection rates in the United States
- Explain the impact and status of PrEP for the HIV prevention goals of the Ending the HIV Epidemic initiative
- Describe updates to the latest PrEP guidelines, including new clinical guidance for the prescription of cabotegravir injections as PrEP
- Identify key changes in testing and monitoring patients who are starting or taking PrEP
- List strategies for identifying and engaging patients who could benefit from HIV prevention (eg, the syndemic approach and status neutral service delivery)

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of **1.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

[Click here for more information and to register!](#)

or Scan Here

